Mainz Biomed BV (MYNZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mainz Biomed BV stock (MYNZ) is currently trading at $0.50. Mainz Biomed BV PS ratio (Price-to-Sales) is 16.01. Analyst consensus price target for MYNZ is $14.00. WallStSmart rates MYNZ as Sell.
- MYNZ PE ratio analysis and historical PE chart
- MYNZ PS ratio (Price-to-Sales) history and trend
- MYNZ intrinsic value — DCF, Graham Number, EPV models
- MYNZ stock price prediction 2025 2026 2027 2028 2029 2030
- MYNZ fair value vs current price
- MYNZ insider transactions and insider buying
- Is MYNZ undervalued or overvalued?
- Mainz Biomed BV financial analysis — revenue, earnings, cash flow
- MYNZ Piotroski F-Score and Altman Z-Score
- MYNZ analyst price target and Smart Rating
Mainz Biomed BV
📊 No data available
Try selecting a different time range
Smart Analysis
Mainz Biomed BV (MYNZ) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Mainz Biomed BV (MYNZ) Key Strengths (0)
Supporting Valuation Data
Mainz Biomed BV (MYNZ) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -44.90%, a shrinking business
Very expensive at 16.0x annual revenue
Very low institutional interest at 6.91%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Mainz Biomed BV (MYNZ) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (16.01), Price/Book (2.79) suggest expensive pricing. Growth concerns include Revenue Growth at -44.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -465.80%, Operating Margin at -2822.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -465.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -44.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MYNZ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MYNZ's Price-to-Sales ratio of 16.01x sits near its historical average of 15.01x (50th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 16.01x set in Mar 2026, and 53% above its historical low of 10.43x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~10.4x, reflecting growing market expectations outpacing revenue growth.
Compare MYNZ with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Mainz Biomed BV (MYNZ) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Mainz Biomed BV operates as a stable business with moderate growth and solid fundamentals. Revenue reached 659,940 with 45% decline year-over-year.
Key Findings
Spending 419% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 45% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Mainz Biomed BV.
Bottom Line
Mainz Biomed BV offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Mainz Biomed BV(MYNZ)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.